Product Pathways - Growth Factors/Cytokines
Human BAFF/TNFSF13B (hBAFF) #5233
Recombinant human BAFF (hBAFF) Ala134-Leu285 (Accession #NP_006564) was expressed in human 293 cells at Cell Signaling Technology.
Recombinant hBAFF contains no "tags" and the nonglycosylated protein has a calculated MW of 15,489. DTT-reduced and non-reduced protein migrate as 16 kDa polypeptides. The expected amino-terminal AVQGP of recombinant hBAFF was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hBAFF. All lots are greater than 98% pure.
The bioactivity of recombinant hBAFF was determined in a cell proliferation assay using mouse splenic B cells. The ED50 of each lot is between 0.5-2 ng/ml.
The purity of recombinant hBAFF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hBAFF and staining overnight with Coomassie Blue.
Less than 0.01 ng endotoxin/1 μg hBAFF.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 10 mM DTT and 20 μg BSA per 1 μg hBAFF. Cystines are not required for bioactivity. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 10 mM DTT. Cystines are not required for bioactivity.
BAFF, a member of the TNF superfamily of proteins, is a homotrimeric transmembrane protein, which is cleaved to produce a soluble cytokine (1). BAFF may also further oligomerize into 60-mer structures (1). BAFF is expressed by neutrophils, macrophages, dendritic cells, activated T cells, and epithelial cells (1,2). BAFF plays a key role in B cell development, survival, and activation (1,3,4). BAFF binds to three distinct receptors, BAFF-R, TACI, and BCMA (1). These receptors are differentially expressed during B cell development and among B cell subsets (1,2,4). While BAFF-R and BCMA bind to the homotrimeric form of BAFF, TACI only binds to membrane bound or higher order BAFF structures (1). The BAFF/ BAFF-R interaction activates both canonical and non-canonical NF-κB pathways, PI3K/Akt, and mTOR (2,4). Activation of the noncanonical NF-κB pathway via BAFF-R is negatively regulated by TRAF3 (5). Elevated levels of BAFF may exacerbate many autoimmune disorders, making it an attractive therapeutic target (2).
- Mackay, F. and Schneider, P. (2009) Nat Rev Immunol 9, 491-502.
- Moisini, I. and Davidson, A. (2009) Clin Exp Immunol 158, 155-63.
- Schiemann, B. et al. (2001) Science 293, 2111-4.
- Khan, W.N. (2009) J Immunol 183, 3561-7.
- Gardam, S. et al. (2008) Immunity 28, 391-401.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 4370 Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb
- 4695 p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb
For Research Use Only. Not For Use In Diagnostic Procedures.